139 related articles for article (PubMed ID: 33357488)
1. Multiple keratoacanthomas in a patient with myelodysplastic syndrome.
Zhu P; Wang Y
Lancet Haematol; 2021 Jan; 8(1):e94. PubMed ID: 33357488
[No Abstract] [Full Text] [Related]
2. Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent.
Randhawa J; Wong S; Atallah E; Olasz E
Int J Dermatol; 2014 Jan; 53(1):e13-4. PubMed ID: 22998756
[No Abstract] [Full Text] [Related]
3. Multiple eruptive keratoacanthomas associated with myelodysplastic syndrome.
Behzad M; Michl C; Pfützner W
J Dtsch Dermatol Ges; 2012 May; 10(5):359-60. PubMed ID: 22525151
[No Abstract] [Full Text] [Related]
4. Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream.
Di Lernia V; Ricci C; Albertini G
J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):626-9. PubMed ID: 15324413
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of topical imiquimod cream on keratoacanthoma: A retrospective single-center study.
Lee JW; Cho KH; Choi CW; Jo SJ
J Am Acad Dermatol; 2022 Sep; 87(3):671-674. PubMed ID: 34474080
[No Abstract] [Full Text] [Related]
6. Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine.
Yoshioka A; Fujiwara S; Kawano H; Nakano H; Taketani S; Matsui T; Katayama Y; Nishigori C
Acta Derm Venereol; 2018 Feb; 98(2):275-277. PubMed ID: 29057424
[No Abstract] [Full Text] [Related]
7. Successful treatment of multiple keratoacanthoma with topical imiquimod and low-dose acitretin.
Barysch MJ; Kamarashev J; Lockwood LL; Dummer R
J Dermatol; 2011 Apr; 38(4):390-2. PubMed ID: 21544945
[No Abstract] [Full Text] [Related]
8. Multiple eruptive keratoacanthomas: a confusing term?
Nofal A; Nofal E
J Dtsch Dermatol Ges; 2013 Aug; 11(8):756. PubMed ID: 23621430
[No Abstract] [Full Text] [Related]
9. A Case of Myelodysplastic Syndrome with Intestinal Behçet's Disease-Like Symptoms Treated by Prednisolone and Azacitidine.
Endo M; Sekikawa A; Tsumura T; Maruo T; Osaki Y
Am J Case Rep; 2015 Nov; 16():827-31. PubMed ID: 26590106
[TBL] [Abstract][Full Text] [Related]
10. [Successful treatment with azacitidine for myelodysplastic syndrome with large vessel vasculitis].
Mishima M; Makita M; Sando Y; Yamamoto Y; Shiote Y; Hara Y; Yamamoto K; Imajo K
Rinsho Ketsueki; 2015 Jan; 56(1):35-7. PubMed ID: 25745966
[TBL] [Abstract][Full Text] [Related]
11. Interstitial granulomatous dermatitis associated with myelodysplastic syndrome - complete clearance under therapy with 5-azacytidine.
Patsinakidis N; Susok L; Hessam S; Othlinghaus N; Möllenhoff K; Stücker M; Altmeyer P; Kreuter A
Acta Derm Venereol; 2014 Nov; 94(6):725-6. PubMed ID: 24573709
[No Abstract] [Full Text] [Related]
12. Multiple and aggressive keratoacanthomas associated with Ferguson-Smith syndrome, successfully treated by cetuximab and cisplatin.
Pham F; Buiret G; Bonnet-Dupeyron MN; Beschet I; Skowron F
Eur J Dermatol; 2021 Apr; 31(2):271-272. PubMed ID: 33871373
[No Abstract] [Full Text] [Related]
13. Azacitidine is effective for the treatment of myelodysplastic syndrome and accompanied Sweet syndrome.
Lin CH; Yeh SP; Lin TY
Ann Hematol; 2015 Nov; 94(11):1925-6. PubMed ID: 26233682
[No Abstract] [Full Text] [Related]
14. Eruptive keratoacanthoma and squamous cell carcinoma complicating imiquimod therapy: response to oral acitretin.
Foxton G; Delaney T
Australas J Dermatol; 2011 Feb; 52(1):66-9. PubMed ID: 21332698
[TBL] [Abstract][Full Text] [Related]
15. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.
Prebet T; Fenaux P; Vey N;
Haematologica; 2016 Oct; 101(10):e427-e428. PubMed ID: 27694503
[No Abstract] [Full Text] [Related]
16. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
Silverman LR
Leuk Res; 2009 Dec; 33 Suppl 2():S18-21. PubMed ID: 20004792
[TBL] [Abstract][Full Text] [Related]
17. Disseminated varicella-zoster virus infection following azacitidine in a patient with myelodysplastic syndrome.
Zhou G; Houldin AD
Clin J Oncol Nurs; 2009 Jun; 13(3):280-4. PubMed ID: 19502185
[No Abstract] [Full Text] [Related]
18. Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.
Hashimoto M; Itonaga H; Nannya Y; Taniguchi H; Fukuda Y; Furumoto T; Fujioka M; Kasai S; Taguchi M; Taniguchi H; Sato S; Sawayama Y; Atogami S; Iwasaki K; Hata T; Soda H; Moriuchi Y; Nakata K; Ogawa S; Miyazaki Y
Intern Med; 2020 Apr; 59(8):1081-1086. PubMed ID: 31875636
[TBL] [Abstract][Full Text] [Related]
19. A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine.
Ham JC; Hoogendijk-van den Akker JM; Verdonck LF
Leuk Lymphoma; 2012 Dec; 53(12):2521-2. PubMed ID: 22530662
[No Abstract] [Full Text] [Related]
20. 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.
Pinto A; Zagonel V
Leukemia; 1993 May; 7 Suppl 1():51-60. PubMed ID: 7683358
[No Abstract] [Full Text] [Related]
[Next] [New Search]
